Darl Moreland joined Accuray in August 2013 as Senior Vice President, Regulatory, Quality and Compliance (RQC). In this role, he has worked to establish the RQC organization as a major part of the overall scalability and sustainability efforts currently underway at Accuray. Previously, Moreland led Quality and Compliance departments at several companies including Alexza Pharmaceuticals and Mentor Corporation.
During his career Moreland has either participated in or has lead teams supporting global approval of numerous pharmaceutical, biotech, combination and medical device products, including two “first in class” products, at companies such as ALZA, Eli Lilly and Company, Guidant, and Mentor.
Moreland earned a B.A. degree in chemistry from Indiana University Purdue University at Indianapolis.
© 2007 - 2016 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi-Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.
Important Safety Information: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.
Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.